Status:
COMPLETED
The Relationship Between CMV* Reactivation and Anti-cytokine Treatment in Critical COVID-19 Patients
Lead Sponsor:
Ramazan Gozukucuk
Conditions:
COVID-19, Cytomegalovirus (CMV), Tocilizumab, Anakinra, Mortality
Eligibility:
All Genders
18-90 years
Brief Summary
The risk of secondary infection is high in critical patients hospitalized with the diagnosis of COVID-19. Immunosuppressive treatments are commonly used in critical COVID-19 patients, and immune dysfu...
Detailed Description
The records of critical patients were reviewed retrospectively. Whether these patients used tocilizumab and/or anakinra and their relationship with CMV reactivation were examined. Furthermore, the rel...
Eligibility Criteria
Inclusion
- Critically ill patients over the age of 18 diagnosed with COVID-19 and patients followed in the intensive care unit.
Exclusion
- Patients under the age of 18 with a mild/moderate course of COVID-19,
- CMV PCR positive before anti-cytokine treatment,
- patients who underwent hematopoietic stem cell transplantation
Key Trial Info
Start Date :
March 15 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 30 2022
Estimated Enrollment :
167 Patients enrolled
Trial Details
Trial ID
NCT05419206
Start Date
March 15 2020
End Date
May 30 2022
Last Update
June 15 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hisar Hospital Intercontinental
Istanbul, Turkey (Türkiye)